Simultaneous modulation of transport and metabolism of acyclovir prodrugs across rabbit cornea: An approach involving enzyme inhibitors

International Journal of Pharmaceutics

Volumn 320, Issue 1-2, 2006, Pages 104-113

  Katragadda, Suresh ^a   Talluri, Ravi S ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Corneal hydrolysis; Enzyme inhibitors; Hydrolytic enzymes; Prodrugs; Transporters

Indexed keywords

ACICLOVIR DERIVATIVE; AMINOPEPTIDASE; BESTATIN; CARBOXYLESTERASE; DYFLOS; ENZYME INHIBITOR; GLYCYLVALACICLOVIR; PHOSPHATE; PHYSOSTIGMINE; TETRAETHYL PYROPHOSPHATE; UNCLASSIFIED DRUG; VALACICLOVIR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; MALE; METABOLIC RATE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ACYCLOVIR; AMINOPEPTIDASES; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL TRANSPORT; CARBOXYLIC ESTER HYDROLASES; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; CORNEA; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HYDROLYSIS; KINETICS; LEUCINE; MALE; MANNITOL; P-CHLOROMERCURIBENZOIC ACID; PEPTIDES; PRODRUGS; RABBITS; VALINE;

EID: 33746404653     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.04.010     Document Type: Article

References (31)

1. Anand B.S., Katragadda S., and Mitra A.K. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. J. Pharmacol. Exp. Ther. 311 (2004) 659-667
2. Anand B.S., and Mitra A.K. Mechanism of corneal permeation of l-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea. Pharm. Res. 19 (2002) 1194-1202
3. Anand B.S., Patel J., and Mitra A.K. Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2. J. Pharmacol. Exp. Ther. 304 (2003) 781-791
4. Ando H.Y., Ho N.F., and Higuchi W.I. Skin as an active metabolizing barrier I: theoretical analysis of topical bioavailability. J. Pharm. Sci. 66 (1977) 1525-1528
5. Balimane P.V., Tamai I., Guo A., Nakanishi T., Kitada H., Leibach F.H., Tsuji A., and Sinko P.J. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 250 (1998) 246-251
6. Bundgaard H., Falch E., and Jensen E. A novel solution-stable, water-soluble prodrug type for drugs containing a hydroxyl or an NH-acidic group. J. Med. Chem. 32 (1989) 2503-2507
7. Curran M., and Noble S. Valganciclovir. Drugs 61 (2001) 1145-1150 discussion, pp. 1151-1142
8. Das M., and Radhakrishnan A.N. Role of peptidases and peptide transport in the intestinal absorption of proteins. World Rev. Nutr. Diet 24 (1976) 58-87
9. Dey S., Patel J., Anand B.S., Jain-Vakkalagadda B., Kaliki P., Pal D., Ganapathy V., and Mitra A.K. Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest. Ophthalmol. Vis. Sci. 44 (2003) 2909-2918
10. Ganapathy M.E., Huang W., Wang H., Ganapathy V., and Leibach F.H. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun. 246 (1998) 470-475
11. Garren K.W., Topp E.M., and Repta A.J. Buccal absorption: III. Simultaneous diffusion and metabolism of an aminopeptidase substrate in the hamster cheek pouch. Pharm. Res. 6 (1989) 966-970
12. Han H., de Vrueh R.L., Rhie J.K., Covitz K.M., Smith P.L., Lee C.P., Oh D.M., Sadee W., and Amidon G.L. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 15 (1998) 1154-1159
13. Han H.K., and Amidon G.L. Targeted prodrug design to optimize drug delivery. AAPS Pharm. Sci. 2 (2000) E6
14. Holmes R.S., and Masters C.J. The developmental multiplicity and isoenzyme status of cavian esterases. Biochim. Biophys. Acta 132 (1967) 379-399
15. Kim I., Chu X.Y., Kim S., Provoda C.J., Lee K.D., and Amidon G.L. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J. Biol. Chem. 278 (2003) 25348-25356
16. Kim Y.S., Nicholson J.A., and Curtis K.J. Intestinal peptide hydrolases: peptide and amino acid absorption. Med. Clin. North Am. 58 (1974) 1397-1412
17. Lee V.H. Esterase activities in adult rabbit eyes. J. Pharm. Sci. 72 (1983) 239-244
18. Lee V.H., Chang S.C., Oshiro C.M., and Smith R.E. Ocular esterase composition in albino and pigmented rabbits: possible implications in ocular prodrug design and evaluation. Curr. Eye Res. 4 (1985) 1117-1125
19. Lee V.H., Iimoto D.S., and Takemoto K.A. Subcellular distribution of esterases in the bovine eye. Curr. Eye Res. 2 (1982) 869-876
20. Lee V.H., Morimoto K.W., and Stratford Jr. R.E. Esterase distribution in the rabbit cornea and its implications in ocular drug bioavailability. Biopharm. Drug Dispos. 3 (1982) 291-300
21. Melby J.C., and St. Cyr M. Comparative studies on absorption and metabolic disposal of water-soluble corticosteroid esters. Metabolism 10 (1961) 75-82
22. Nichifor M., and Schacht E.H. Chemical and enzymatic hydrolysis of dipeptide derivatives of 5-fluorouracil. J. Control. Rel. 47 (1997) 271-281
23. Okuda J., and Horiguchi N. Determination of carboxylesterase in rat tissues and blood using riboflavin-5′-monobutyrate. Chem. Pharm. Bull. (Tokyo) 28 (1980) 181-188
24. Perry C.M., and Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52 (1996) 754-772
25. Pescovitz M.D., Rabkin J., Merion R.M., Paya C.V., Pirsch J., Freeman R.B., O'Grady J., Robinson C., To Z., Wren K., Banken L., Buhles W., and Brown F. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chemother. 44 (2000) 2811-2815
26. Roy S.D., and Manoukian E. Permeability of ketorolac acid and its ester analogs (prodrug) through human cadaver skin. J. Pharm. Sci. 83 (1994) 1548-1553
27. Smiley M.L., Murray A., and de Miranda P. Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Adv. Exp. Med. Biol. 394 (1996) 33-39
28. Stratford Jr. R.E., and Lee V.H. Ocular aminopeptidase activity and distribution in the albino rabbit. Curr. Eye Res. 4 (1985) 995-999
29. Tak R.V., Pal D., Gao H., Dey S., and Mitra A.K. Transport of acyclovir ester prodrugs through rabbit cornea and SIRC-rabbit corneal epithelial cell line. J. Pharm. Sci. 90 (2001) 1505-1515
30. Watanabe K.A., Matsuda A., Halat M.J., Hollenberg D.H., Nisselbaum J.S., and Fox J.J. Nucleosides 114. 5′-O-Glucuronides of 5-fluorouridine and 5-fluorocytidine. Masked precursors of anticancer nucleosides. J. Med. Chem. 24 (1981) 893-897
31. Weller S., Blum M.R., Doucette M., Burnette T., Cederberg D.M., de Miranda P., and Smiley M.L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 54 (1993) 595-605